About Broncus
Broncus is a company based in San Jose (United States) founded in 1997. Broncus has raised $82.5 million across 5 funding rounds from investors including Intuitive, Qiming Venture Partners and Abingworth. The company has 200 employees as of December 31, 2024. Broncus has completed 1 acquisition, including Uptake Medical. Broncus operates in a competitive market with competitors including Oncimmune, Biodesix, OncoCyte, Riverain Tech and ONCOHOST, among others.
- Headquarter San Jose, United States
- Employees 200 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Broncus Holding Corp.
-
Annual Revenue
$8.17 M (USD)-20.97as on Dec 31, 2024
-
Net Profit
-$15.38 M (USD)45.7as on Dec 31, 2024
-
EBITDA
-$19.37 M (USD)36.71as on Dec 31, 2024
-
Total Equity Funding
$82.5 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
Intuitive
& 23 more
-
Employee Count
200
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Broncus
Broncus is a publicly listed company on the HKEX with ticker symbol 2216 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Broncus
Broncus has successfully raised a total of $82.5M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Broncus
Broncus has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Intuitive, Qiming Venture Partners and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
FountainVest is involved in investment or financial services.
|
Locked | Locked | Locked | |
|
Exome Asset Management is focused on healthcare industry investments.
|
Locked | Locked | Locked | |
|
Summer Capital is engaged in multi-strategy investment advisory services.
|
Locked | Locked | Locked |
Investor details for Broncus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Broncus
Broncus has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Uptake Medical.
Investment portfolio details for Broncus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Targeted vapor therapy is developed for endoscopic lung volume reduction.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Broncus
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Broncus
Detailed financials for Broncus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Broncus Comparisons
Peer comparison for Broncus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Broncus
Broncus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oncimmune, Biodesix, OncoCyte, Riverain Tech and ONCOHOST, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Diagnostics and risk assessment solutions for lung cancer are developed.
|
|
| Locked | Locked | Locked |
Cancer detection diagnostics assays are developed and offered.
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Software tools are developed for early lung disease detection.
|
|
| Locked | Locked | Locked |
AI-based proteomic analysis for oncology therapy planning is offered.
|
Detailed competitors of Broncus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Broncus
Complete news archive for Broncus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Broncus
Broncus was founded in 1997 and raised its 1st funding round 9 years after it was founded.
Broncus is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Broncus is a funded company, having raised a total of $82.5M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Broncus is 200.
Annual revenue of Broncus is $8.17M as on Dec 31, 2024.
Broncus was founded in 1997 and is headquartered in San Jose, United States. Operations focus on the medical device sector, with minimally invasive navigation, diagnostic, and therapeutic solutions provided for lung diseases. An intellectual property portfolio comprising 75 patents, including issued, licensed, and pending ones, is maintained. The LungPoint Virtual Bronchoscopic Navigation System is utilized for image-guided planning and navigation to lung tumors in a commercial-stage context.
Yes, Broncus is publicly traded on HKEX under the ticker symbol 2216.
Broncus has made 1 acquisition, including Uptake Medical.
Broncus has 24 investors. Key investors include Intuitive, Qiming Venture Partners, Abingworth, HBM Healthcare Investments, and Japan Asia Investment.
The ticker symbol of Broncus is 2216 on HKEX.